Study component	Instrument	Number of re- spondents	Frequency of re- sponse	Average time per response (Minutes/Hour)	Annual burden hours
	Saliva Protocol and Form (Attach- ment 15).	742	3	10/60 (.167)	371
	Heart Rate Monitor Log (Attach- ment 8).	34	1	35/60 (.583)	20
	Physical Activity Monitor Log (Ac- celerometer/Inclinometer) (At- tachment 12).	742	2	35/60 (.583)	866
Total					15,060

TABLE 1—ESTIMATES OF ANNUAL BURDEN HOURS—Continued

Request for Comments: Written comments and/or suggestions from the public and affected agencies should address one or more of the following points: (1) Evaluate whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) Enhance the quality, utility, and clarity of the information to be collected; and (4) Minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

Direct Comments to OMB: Written comments and/or suggestions regarding the item(s) contained in this notice, especially regarding the estimated public burden and associated response time, should be directed to the Attention: NIH Desk Officer, Office of Management and Budget, at OIRA submission@omb.eop.gov or by fax to 202–395–6974. To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact Heather Bowles, Risk Factor Monitoring and Methods Branch, Division of Cancer Control and Population Sciences, National Cancer Institute, 6130 Executive Blvd. MSC 7344, Bethesda, MD 20892–7335 or call non-toll-free number 301–496–7344 or e-mail your request, including your address to: bowleshr@mail.nih.gov.

*Comments Due Date:* Comments regarding this information collection are best assured of having their full effect if received within 30 days of the date of this publication. Dated: May 9, 2011. Vivian Horovitch-Kelley,

NCI Project Clearance Liaison, National Institutes of Health.

[FR Doc. 2011–11824 Filed 5–12–11; 8:45 am] BILLING CODE 4140–01–P

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### National Institutes of Health

## National Institute of Neurological Disorders and Stroke; Notice of Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of meetings of the National Advisory Neurological Disorders and Stroke Council.

The meetings will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Advisory Neurological Disorders and Stroke Council, Clinical Trials Subcommittee.

Date: May 25, 2011.

*Closed:* 6:30 p.m. to 8 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814.

*Open:* 8 p.m. to 8:30 p.m.

Agenda: To discuss clinical trials policy. Place: Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin

Avenue, Bethesda, MD 20814.

Contact Person: Petra Kaufmann, MD, Director, Office of Clinical Research—NINDS, National Institutes of Health, Neuroscience Center—Room 2216, 6001 Executive Blvd., Bethesda, MD 20892, 301–496– 9135,Kaufmanp2@ninds.nih.gov.

This notice is being published less than 15 days prior to the meeting due to timing limitations imposed by the review funding cycle.

Name of Committee: National Advisory Neurological Disorders and Stroke Council, Basic and Preclinical Programs Subcommittee.

*Date:* May 26, 2011.

*Open:* 8 a.m. to 9 a.m.

*Agenda:* To discuss basic and preclinical programs policy.

*Place:* National Institutes of Health,

Building 31, C Wing, Conference Room 10,

Bethesda, MD 20892.

Closed: 9 a.m. to 9:30 a.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Building 31, C Wing, Conference Room 10, Bethesda, MD 20892.

Contact Person: Walter Joseph Koroshetz, MD, Deputy Director, NINDS, Building 31, Room 8A52, 31 Center Drive, MSC 2540, 301–496–3167, Koroshetzw@ninds.nih.gov.

This notice is being published less than 15 days prior to the meeting due to timing limitations imposed by the review funding cycle.

*Name of Committee:* National Advisory Neurological Disorders and Stroke Council Training, Career Development, and Special Programs Subcommittee.

Date: May 26, 2011.

*Open:* 9:30 a.m. to 10:30 a.m.

*Agenda:* To discuss the training plan of the institute.

*Place:* National Institutes of Health, Building 31, C Wing, Conference Room 10, Bethesda, MD 20892.

*Contact Person:* Stephen J. Korn, PhD, Training and Special Programs Officer, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 6001 Executive Blvd., Suite 2154, MSC 9527, Bethesda, MD 20892–9527, 301–496–4188.

This notice is being published less than 15 days prior to the meeting due to timing limitations imposed by the review funding cycle.

In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver's license, or passport) and to state the purpose of their visit.

Information is also available on the Institute's/Center's home page: http:// www.ninds.nih.gov, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance

Program Nos. 93.853, Clinical Research Related to Neurological Disorders; 93.854, Biological Basis Research in the Neurosciences, National Institutes of Health, HHS)

Dated: May 6, 2011.

Jennifer S. Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2011–11779 Filed 5–12–11; 8:45 am] BILLING CODE 4140–01–P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

# National Institutes of Health

#### Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App), notice is hereby given of a meeting of the Advisory Committee to the Director, National Institutes of Health (NIH).

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 USC, as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

*Name of Committee:* Advisory Committee to the Director, NIH.

Date: June 9–10, 2011. Closed: June 9, 2011, 9:30 a.m. to 10:30 a.m.

*Agenda:* Review of the Pioneer and Innovator Awards.

*Place:* National Institutes of Health, Building 31, C-Wing, 6th Floor, Conference Room 6, 31 Center Drive, Bethesda, MD 20892.

*Open:* June 9, 2011, 10:30 a.m. to 5 p.m. June 10, 2011, 8 a.m. to 4 p.m.

Agenda: NIH Director's Report, NIH updates, and other committee business.

*Place:* National Institutes of Health, Building 31, C-Wing, 6th Floor, Conference Room 6, 31 Center Drive, Bethesda, MD 20852.

*Contact Person:* Gretchen Wood, Senior Assistant to the Deputy Director, Office of the Director, National Institutes of Health, One Center Drive, Building 1, Room 114, Bethesda, MD 20892, *woodgs@od.nih.gov.* 

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver's license, or passport) and to state the purpose of their visit.

Information is also available on the Institute's/Center's home page: http:// www.nih.gov/about/director/acd.htm, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.14, Intramural Research Training Award; 93.22, Clinical Research Loan Repayment Program for Individuals from Disadvantaged Backgrounds; 93.232, Loan Repayment Program for Research Generally; 93.39, Academic Research Enhancement Award; 93.936, NIH Acquired Immunodeficiency Syndrome Research Loan Repayment Program; 93.187, Undergraduate Scholarship Program for Individuals from Disadvantaged Backgrounds, National Institutes of Health, HHS)

Dated: May 5, 2011.

#### Jennifer S. Spaeth.

Director, Office of Federal Advisory Committee Policy. [FR Doc. 2011–11791 Filed 5–12–11; 8:45 am] BILLING CODE 4140–01–P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

# National Institutes of Health

## National Institute of Biomedical Imaging and Bioengineering; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Biomedical Imaging and Bioengineering Special Emphasis Panel.

*Date:* June 3, 2011.

*Time:* 1 p.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Two Democracy Plaza, 6707 Democracy Boulevard, Bethesda, MD 20892.

*Contact Person:* Ruixia Zhou, PhD, Scientific Review Officer, 6707 Democracy Boulevard, Democracy Two Building, Suite 957, Bethesda, MD 20892, 301–496–4773, *zhour@mail.nih.gov.* 

Dated: May 9, 2011.

Jennifer S. Spaeth,

Director, Office of Federal Advisory Committee Policy. [FR Doc. 2011–11798 Filed 5–12–11; 8:45 am]

BILLING CODE 4140-01-P

#### DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### National Institutes of Health

#### National Center for Research Resources; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant